Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

Launched by DUKE UNIVERSITY · Jul 7, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how to help patients with a condition called non-valvular atrial fibrillation (NVAF) make better decisions about taking a medication that can lower their risk of having a stroke. The researchers believe that by using a special decision support tool, they can help improve the quality of the decisions patients make about their treatment, particularly for Black patients. The study will also check if this tool encourages more patients to start taking the medication.

To participate in this trial, you need to be at least 18 years old, either Black or White, and have a diagnosis of NVAF with a specific score indicating your risk for stroke. You’ll be eligible if you are visiting a primary care or cardiology clinic for the first time to discuss starting this medication. Unfortunately, if you can't speak English or provide informed consent, you won't be able to join the study. While the trial is not yet recruiting participants, it aims to understand if this tool can make a positive difference in decision-making for patients at risk of stroke.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Black and White adults greater than or equal to 18 years of age
• • Clinical diagnosis of NVAF
• • CHA2DS2-VASc score greater than or equal to 2
• • New patient visit for initiation of oral anticoagulation at primary care and cardiology clinics
• Exclusion Criteria:
• • Unable to speak English
• • Unable to provide informed consent